Abstracts

Citation

Gwendolyn B. Scott, M.D., John H. Rodman, Pharm.D., Walter A. Scott, Ph.D., David E. Shapiro, Ph.D., Sharon Huang, M.S., Elizabeth (Betsy) Smith, M.D., Lynne M. Mofenson, M.D., F.A.A.P., Heather D. Watts, M.D., Mary Jo O'Sullivan, M.D. Pharmacokinetic and virologic resopnse to ritonavir (RTV) in combination with zidovudine (ZVD) and lamivudine (3TC) in HIV-1 infected pregnant women and their infants. Presented at: 9th Conference on Retroviruses & Opportunistic Infections.

Citation

Lisa Aaron, Grace Montepiedra, Kamu Gausi, Paolo Denti, Renee Browning, Gerhard Theron, Adriana Weinberg, Teacler Nematadzira, Amita Gupta, IMPAACT P1078 TB APPRISE Study Team, Patrica Mandima, Enid Kabugho, Mandisa Nyati. Pharmacokinetic-pharmacogenetic-pharmacodynamic analysis of isoniazid and efavirenz for predicting adverse pregnancy outcomes in women with HIV. Presented at: The Union World Conference on Lung Health.

Citation

John S. Lambert, M.D. Pharmacokinetics (PK) & Safety of Hyperimmune HIV Immunoglobulin (HIVIG) in Pregnant HIV+ Women.

Citation

Jennifer J. Kiser, Pharm.D., R Zhu, Sharon Appelbaum Nachman, M.D., Carol K. Mitchell, George D. McSherry, M.D., Shabir A. Madhi, M.D., Mark F. Cotton, MMED, Ph.D., MB ChB, Raziya Bobat, M.D., Soyeon Kim, Ph.D., Heiner Seifart, Cedric John Werely, D Z D'Argenio, Courtney V. Fletcher, Pharm.D. Pharmacokinetics (PK) and genetics (PG) of isoniazid (INH) in South African HIV-exposed infants. Presented at: 48th Intersci Conf on Antimicrobial Agents & Chemotherapy.

Citation

John H. Rodman, Pharm.D., Patricia M. Flynn, M.D., M.S., David E. Shapiro, Ph.D., Arlene D. Bardeguez, M.D., M.P.H., F.A.C.O.G., Sharon Huang, M.S., Susan A. Fiscus, Ph.D., Koen Van Rompay, D.V.M., Ph.D., James F. Rooney, M.D., Lynne M. Mofenson, M.D., F.A.A.P., Patrick Jean-Philippe, M.D. Pharmacokinetics (PK) and safety of tenofovir disoproxil fumarate (TDF) in HIV-1 infected pregnant women and their infants. Presented at: 13th Conference on Retroviruses and Opportunistic Infections.

Citation

Russell B. Van Dyke, M.D. Pharmacokinetics (PK) and Tolerance of Intravenous Pentamidine (IV-P) in HIV-Infected Children.

Citation

Jennifer J. Kiser, Pharm.D., Richard M. Rutstein, M.D., Grace M. Aldrovandi, MD, Pearl Samson, M.S., Bobbie L. Graham, B.S., Steven M. Schnittman, M.D., Elizabeth (Betsy) Smith, M.D., Lynne M. Mofenson, M.D., F.A.A.P., Courtney V. Fletcher, Pharm.D. Pharmacokinetics (PK) of atazanivir/ritonavir (ATV/RTV) in HIV-infected infants, children, and adolescents: Pediatric AIDS Clinical Trials Group (PACTG) 1020A. Presented at: 12th Conference on Retroviruses and Opportunistic Infections.

Citation

Brian Robbins, Ph.D., Peter Havens, M.D., Edmund Capparelli, Pharm.D., Ellen Gould Chadwick, M.D., Ram Yogev, M.D., Leslie Serchuck, M.D., Carol J. Worrell, M.D., Carmelita Alvero, Barbara E. Heckman, B.S. Pharmacokinetics (PK) of high-dose lopinavir (LPV)/Ritonavir (r) with and without saquinavir (SQV) or non-nucleoside reverse transcriptase inhibitors (NNRTIs) in HIV infected pediatric and adolescent patients previously treated with protease inhibitors (P. Presented at: 14th Conference on Retroviruses and Opportunistic Infections.

Citation

John S. Lambert, M.D. Pharmacokinetics (PK) of Hyperimmune HIV Immunoglobulin (HIVIG) in HIV+ Pregnant Women & Newborns.

Citation

Mark Mirochnick, M.D., Yvonne J. Bryson, M.D., Alice M. Stek, M.D., Lynne M. Mofenson, M.D., F.A.A.P., James D. Connor, M.D., Heather D. Watts, M.D., Sharon Huang, M.S., Michael Hughes, Ph.D., Bethann Cunningham, B.S., Michael Hughes, Ph.D., Lynette Purdue, Pharm.D., Yetemegnu Asfaw, B.S., Elizabeth (Betsy) Smith, M.D. Pharmacokinetics (PK) of Nelfinavir (NFV) and its M8 Metabolite in Pregnant HIV-Infected Women and Their Infants: PACTG 353.